Prenetics Global Limited (NASDAQ:PRE) Short Interest Update

Prenetics Global Limited (NASDAQ:PRE) was the target of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 41,900 shares, a growth of 23.6% from the November 30th total of 33,900 shares. Based on an average trading volume of 14,000 shares, the days-to-cover ratio is presently 3.0 days. Approximately 0.5% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $9.00 price target on shares of Prenetics Global in a report on Wednesday, December 4th.

Prenetics Global Stock Down 0.5 %

Shares of NASDAQ:PRE traded down $0.03 during trading on Tuesday, reaching $5.80. 10,471 shares of the company traded hands, compared to its average volume of 47,859. Prenetics Global has a 1-year low of $2.85 and a 1-year high of $7.84. The firm has a fifty day simple moving average of $4.90 and a 200 day simple moving average of $5.11. The firm has a market cap of $52.99 million, a P/E ratio of -1.45 and a beta of -0.18.

Prenetics Global (NASDAQ:PRE) last released its quarterly earnings data on Monday, October 7th. The company reported ($0.88) earnings per share (EPS) for the quarter. The business had revenue of $5.94 million during the quarter. Prenetics Global had a negative net margin of 191.73% and a negative return on equity of 16.45%. As a group, research analysts anticipate that Prenetics Global will post -3.3 EPS for the current year.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.